Valuation: Satellos Bioscience Inc.

Market Cap 202M 174M 162M 149M 280M 19.34B 284M 1.91B 749M 9.7B 760M 743M 32.06B P/E 2026 *
-4.57x
P/E 2027 * -6.07x
Enterprise Value 101M 86.37M 80.65M 74M 139M 9.62B 141M 952M 373M 4.83B 378M 370M 15.96B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.33%
Yield 2026 *
-
Yield 2027 * -
1 day+2.30%
1 week-0.07%
Current month-1.43%
1 month+17.75%
3 months+44.20%
6 months-9.51%
Current year+74.24%
1 week 13.3
Extreme 13.3
14.5
1 month 11.39
Extreme 11.39
14.99
Current year 7.67
Extreme 7.67
18.98
1 year 6.96
Extreme 6.960002
18.98
3 years 3.48
Extreme 3.480001
18.98
5 years 2.58
Extreme 2.580001
21.48
10 years 2.58
Extreme 2.580001
22.8
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2018
Chief Tech/Sci/R&D Officer - 01/05/2018
Director of Finance/CFO - 01/09/2023
Director TitleAgeSince
Chairman 59 01/07/2018
Director/Board Member 50 01/03/2018
Director/Board Member 70 01/07/2012
Date Insider Type Main position Quantity % Market Cap.
7/14/26 A Buy

Director

2,575 0.0124%
7/14/26 A Buy

Director

939 0.0045%
7/14/26 A Buy

Director

370 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
+2.30%-0.07%+88.52%+187.50% 202M
-1.90%+2.37%+69.11%+110.88% 73.45B
+0.87%+15.32%+56.99%+92.41% 62.99B
+0.40%-2.42%+1.47%+486.70% 28.05B
-1.40%+4.18%+54.52%+19.60% 25.42B
+20.05%+20.43%+0.26%-4.97% 23.3B
+2.28%+5.65%+42.00%-13.75% 19.45B
0.00%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+17.17%+534.55% 16.53B
+2.36%+7.91%+44.90%+154.40% 13.16B
Average +2.15%+2.03%+61.89%+199.12% 28.07B
Weighted average by Cap. +1.34%+4.38%+57.85%+165.07%

Financials

2026 *2027 *
Net sales - -
Net income -49.21M -42.21M -39.42M -36.16M -68M -4.7B -69.12M -465M -182M -2.36B -185M -181M -7.8B -62.05M -53.23M -49.7M -45.6M -85.75M -5.93B -87.16M -586M -230M -2.97B -233M -228M -9.83B
Net Debt -102M -87.15M -81.38M -74.66M -140M -9.71B -143M -960M -376M -4.87B -381M -373M -16.1B -119M -102M -95.32M -87.45M -164M -11.37B -167M -1.12B -440M -5.7B -447M -437M -18.86B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
19/08/26 CA$13.80 +2.30% 14,293
18/08/26 CA$13.49 -0.81% 5,676
17/08/26 CA$13.60 +1.64% 6,730
14/08/26 CA$13.38 -3.39% 6,883
13/08/26 CA$13.85 +0.29% 3,113
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.49CAD
Average target price
17.67CAD
Spread / Average Target
+30.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock